RT @sloan_kettering: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/4n9XdrWZGt
Thank you @Aiims1742 ! We are fortunate to have helped identify many of the pts for this remarkable trial via pan-cancer #MSKimpact (https://t.co/uULp1bOKYt) & a complementary targeted RNAseq assay, with confirmation by panTRK IHC (https://t.co/Ti9KHK9
RT @RielyMD: A great team put together this impressive report on targeting TRK fusion cancers (@alexdrilon @DrSarcoma @dhymanNYC among othe…
A great team put together this impressive report on targeting TRK fusion cancers (@alexdrilon @DrSarcoma @dhymanNYC among others) https://t.co/7QpUvoMcpu
On the power of Precision Medicine: Efficacy of LOXO’s larotrectinib in Trk-Fusion positive cancers https://t.co/NYz4OZ8jAt
On TRacK to true precision oncology: NEJM https://t.co/foSGXOFc0a
RT @DavidHongMD: Honored to have been a part of this landmark study! https://t.co/xttbXUaoCy
Man, it's a big week when this is the second most interesting article in the NEJM... https://t.co/MRFmDXXKtW
Strong work! Lots to do to figure out how to build on this perhaps before @VinayPrasad82 agrees it’s a breakthrough..but we’re making progress https://t.co/FiEX7b4Rwj
Congrats @alexdrilon! https://t.co/nOa9QO0WCB
TRK fusion and cancer. Larotrectinib very promising! https://t.co/WfpF8HoyoF @OncoNerd @imforero https://t.co/S3ktlJNMk7
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are highly sensitive to TRK inhibition w/ larotrectinib in cancers in adults and children. https://t.co/Kn2LEbiNKm
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @maljurf100: NEJM Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Chi…
Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistance mechanisms to inform the next therapy in same patients, all in context of clinical trial - kudos @dhymanNYC et al https://t.co/NY2i
RT @IshwariaMD: Bravo, @DavidHongMD!!👏👏 #Larotrectinib approaches the ideal that we work toward - tumor shrinkage that lasts with minimal s…
Great story and editorial on TRK targeting @FAndreMD gives superb commentary https://t.co/0ETdcGW8yQ
RT @hpcprogrammer: I just came here to share this graph https://t.co/EoBpN3ho94
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
Honored to have been a part of this landmark study! https://t.co/xttbXUaoCy
I just came here to share this graph https://t.co/EoBpN3ho94
RT @IshwariaMD: Bravo, @DavidHongMD!!👏👏 #Larotrectinib approaches the ideal that we work toward - tumor shrinkage that lasts with minimal s…
RT @VivekSubbiah: Congrats 🎈🎉🍾! @DavidHongMD and @dhymanNYC ! https://t.co/JDEsiIY87g
RT @roelverhaak: Oncogene fusions: optimal therapeutic targets! Many more to be discovered at https://t.co/9dGJ695Nkx https://t.co/a5BvMp3F…
Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children https://t.co/Y1eUWvNq9D
TRK Fusion陽性がん患者さんに対するLarotrectinib の有用性。NEJMに出でました!! https://t.co/GMxXysAYu8
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
Congrats to @sloan_kettering colleagues @alexdrilon and David Hyman for leading development of fantastic option for patients with this rare driver. One of the key indirect benefits of "NGS" is speeding development of agents like this. https://t.co/HFXJrd5x
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @roelverhaak: Oncogene fusions: optimal therapeutic targets! Many more to be discovered at https://t.co/9dGJ695Nkx https://t.co/a5BvMp3F…
RT @VivekSubbiah: Congrats 🎈🎉🍾! @DavidHongMD and @dhymanNYC ! https://t.co/JDEsiIY87g
We heard @dhymanNYC speak this month about @sloan_kettering basket trials, so much potential for patients. Two children who would have needed limbs amputation enrolled in the #Larotrectinib basket trial & had limb sparing surgery instead. Just inspirin
Bravo, @DavidHongMD!!👏👏 #Larotrectinib approaches the ideal that we work toward - tumor shrinkage that lasts with minimal side effects!!! A breakthrough for patients w #TRK Fusion–Positive #Cancer via @NEJM https://t.co/Eq3kcxruoE https://t.co/AHbdBgICsr
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
Absolutely groundbreaking stuff. https://t.co/DMMFjwrl3e
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
Keenly awaited publication of TRK fusion inhibitor Larotrectinib. Will need to discuss in our journal club @UKMarkey - @RAP_MD86 @SusanneArnoldMD https://t.co/aUvnslryZJ
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
Congrats 🎈🎉🍾! @DavidHongMD and @dhymanNYC ! https://t.co/JDEsiIY87g
RT @roelverhaak: Oncogene fusions: optimal therapeutic targets! Many more to be discovered at https://t.co/9dGJ695Nkx https://t.co/a5BvMp3F…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
NEJM Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. https://t.co/FCMLP7Z2wg https://t.co/PoP8NoovmN
Oncogene fusions: optimal therapeutic targets! Many more to be discovered at https://t.co/9dGJ695Nkx https://t.co/a5BvMp3F9U
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
Congrats Michael Cox George Demetri @weldeiry Luis E Raez and many friends in the authors list of this great work! https://t.co/mM4WZgvBOG
Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/EFIEKdFC6N #LCSM
Larotrectinib produced response in 75% of #cancer patients, regardless of age, tissue of origin, or TRK fusion partner, with mild toxic effects. Full trial results: https://t.co/rhm49T26SD https://t.co/unr5cR2yBL
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/sxiMUDs587
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
$LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of drug dev in Rare Genomic Entities https://t.co/GgSQw18SHy https://t.co/JANLepCtJC
RT @teamoncology: An impressive list of cancers with TRK fusion responding to a TRK inhibitor. Co-leader of the study is @DavidHongMD from…
RT @sloan_kettering: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/4n9XdrWZGt